NCT02436798View on ClinicalTrials.gov

5-HT3 Antagonists (Antiemetics) and Cardiac Safety

CompletedOBSERVATIONAL
Enrollment

266

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Adverse Reaction to Other Drugs and Medicines
Interventions
DRUG

Ondansetron

All patients will be receiving treatment with ondansetron as part of standard care.

Trial Locations (1)

V6H 3V4

Children's and Women's Health Centre of British Columbia, Vancouver

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of British Columbia

OTHER

NCT02436798 - 5-HT3 Antagonists (Antiemetics) and Cardiac Safety | Biotech Hunter | Biotech Hunter